Pharmacy and Drug Control Department, Ministry of Public Health, Doha, Qatar.
College of Pharmacy, Qatar University, Doha, Qatar.
Res Social Adm Pharm. 2020 Jun;16(6):793-799. doi: 10.1016/j.sapharm.2019.08.038. Epub 2019 Sep 3.
The importance of providing accurate medication information that can be easily comprehended by patients to subsequently best use their medication(s) has been widely reported in the literature. Patient information leaflet (PIL) is a supporting tool aiding patients to make decisions about their treatment plan and improve patient-clinician communication and thus medication adherence. PIL is the written document produced by the pharmaceutical manufacturers and packed with the medicine. The available PILs do not consider cultural and behavioral perspectives of diverse populations residing in a country like Qatar. Consumer medication information (CMI) is written information about prescription drugs developed by organizations or individuals other than a drug's manufacturer that is intended for distribution to consumers at the time of drug dispensing.
To investigate the impact of customized CMI (C-CMI) on health-related quality of life (HRQoL) among type 2 diabetes mellitus (T2DM) patients in Qatar.
This was a randomized controlled intervention study, in which the intervention group patients received C-CMI and the control group patients received usual care. HRQoL was measured using the EQ-5D-5L questionnaire and EQ visual analog scale (EQ-VAS) at three intervals [i.e. baseline, after 3 months and 6 months].
The EQ-5D-5L index value for the intervention group exhibited sustained improvement from baseline to the third visit. There was a statistically significant difference between groups in the HRQoL utility value (represented as EQ index) at 6 months (0.939 vs. 0.796; p = 0.019). Similarly, the intervention group compared with the control group had significantly greater EQ-VAS at 6 months (90% vs. 80%; p = 0.003).
The impact of C-CMI on health outcomes of T2DM patients in Qatar reported improvement in HRQoL indicators among the intervention patients. The study built a platform for health policymakers and regulatory agencies to consider the provision of C-CMI in multiple languages.
为患者提供能够轻松理解的准确用药信息，以便患者更好地使用药物，这一点已在文献中得到广泛报道。患者用药信息单（PIL）是一种辅助工具，可以帮助患者做出关于治疗计划的决策，改善医患沟通，从而提高用药依从性。PIL 是制药商制作并随药品包装的书面文件。现有的 PIL 并未考虑到居住在卡塔尔这样的国家的不同人群的文化和行为观点。消费者用药信息（CMI）是由制药商以外的组织或个人编写的关于处方药的信息，旨在在配药时分发给消费者。
调查定制消费者用药信息（C-CMI）对卡塔尔 2 型糖尿病（T2DM）患者健康相关生活质量（HRQoL）的影响。
这是一项随机对照干预研究，其中干预组患者接受 C-CMI，对照组患者接受常规护理。使用 EQ-5D-5L 问卷和 EQ 视觉模拟量表（EQ-VAS）在三个时间点（基线、3 个月和 6 个月）测量 HRQoL。
干预组的 EQ-5D-5L 指数值从基线到第三次就诊持续改善。在 6 个月时，两组之间在 HRQoL 效用值（表示为 EQ 指数）方面存在统计学显著差异（0.939 比 0.796；p=0.019）。同样，干预组在 6 个月时的 EQ-VAS 显著高于对照组（90%比 80%；p=0.003）。
C-CMI 对卡塔尔 T2DM 患者健康结果的影响报告称，干预组患者的 HRQoL 指标有所改善。该研究为卫生政策制定者和监管机构提供了一个平台，使其可以考虑以多种语言提供 C-CMI。
